P719 Determinants of tobacco consumption in the Swiss IBD cohort
Grueber M.*1, Clair Willi C.2, Allez M.3, Biedermann L.4, Fournier N.5, Schöpfer A.6, Vavricka S.7, Juillerat P.8, Macpherson A.J.9
1Inselspital, Bern, Department of Gastroenterology, Bern, Switzerland 2CHUV, PMU, Lausanne, Switzerland 3Hôpital Saint-Louis, Gastroenterology, Lausanne, France 4Universitätsspital, Gastroenterology, Zürich, Switzerland 5CHUV, Statistics, Lausanne, Switzerland 6CHUV, Gastroenterology, Lausanne, Switzerland 7Stadtspital Triemli, Gastroenterology, Zürich, Switzerland 8Inselspital, Gastroenterology, Bern, Switzerland 9Inselpital, Gastroenterology, Bern, Switzerland
Tobacco consumption is an important environmental factor in inflammatory bowel diseases (IBD). Our aim was to identified characteristics associated with smoking in Crohn's disease (CD) and Ulcerative colitis (UC).
Adult UC and CD patients included in the Swiss IBD cohort study (SIBDCS) from Nov. 2006 to Nov. 2015 were asked about their smoking status. Patients were separated in two groups (active smokers vs. non-smokers). A logistic regression analysis was performed with smoking as main outcome.
999 UC and 1386 CD patients were included in the study. In the univariate analysis, smoking was positively associated with the female gender in CD patients. Smoking CD patients had more stenosis and used significantly more oral Budesonide, whereas UC patients used more topical treatments. A high anxiety and depression score was significantly associated with smoking among CD patients. The use of invalidity insurance was significantly higher in smoking UC and CD patients in the univariate analysis and was confirmed in the multivariate analysis (OR 1.8 [1.1–3.0], p=0.02 for UC and OR 3.4 [1.3–9.1], p=0.015 for CD).
After adjustment for disease pattern and activity, the only factor significantly associated with tobacco consumption in IBD patients is the need for invalidity insurance.
This positive association between active smoking and invalidity insurance is, however, not specific to IBD patients but also known in the Swiss population